HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

Heparin Pretreatment in STEACS Treatment: A New Old Ally?

The treatment of ST-segment elevation acute coronary syndromes (STEACS) is undoubtedly reperfusion therapy with primary percutaneous coronary...
solaci -
Learn More
Other

ESC 2022 | INVICTUS and PRE18FFIR

On the 3erd day of the European Cardiology Congress 2022 the INVICTUS study was presented, including 4565...
solaci -
Learn More
Antiplatelet

Adherence to P2Y12 Inhibitors in Acute Coronary Syndrome: Prognosis

Non-adherence to medication in patients with acute coronary syndrome (ACS) remains to be solved; the use of...
solaci -
Learn More
Other

ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function

About 30 to 80% of patients with heart failure (HF) have some sort of cognitive impairment, with...
solaci -
Learn More
Other

ESC 2022 | SECURE Trial

This study, presented by Dr. Valentin Fuster, focused on the importance of medical treatment compliance, initially showing...
solaci -
Learn More
Other

ESC 2022 | TIME STUDY

The TIME study, presented by Dr. Thomas MacDonald, is a randomized study of over 21,000 patients with...
solaci -
Learn More
Antiplatelet

Ticagrelor Monotherapy: Valid after 12 Months?

Recent studies on antiplatelet antiaggregation support the use of short dual antiaggregation therapy (DAPT), even in unforeseen...
solaci -
Learn More
Day 2

SOLACI-SOCIME 2022 | El Desafío de PCI en pacientes con HBR, by Dr. Aníbal Damonte

Read the most outstanding articles from the second day of the SOLACI-SOCIME 2022 Congress. In this case, consult...
solaci -
Learn More